Claims for Patent: 7,709,457

Summary for Patent: 7,709,457

Title:	Methods and compositions for delivery of pharmaceutical agents
Abstract:	Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-.beta.-cyclodextrin) and the pharmaceutical agent comprises a polynucleotide and either a cationic lipid, a cationic polymer or a dendrimer. Improved methods for transfecting polynucleotides into cells thus are also provided, using cationic lipids, cationic polymers or dendrimers and solubilized cholesterol, wherein the transfection efficiency is enhanced compared to use of cationic lipids, cationic polymers or dendrimers alone. Preferred methods of the invention involve transfecting polynucleotides into urothelial cells, preferably for therapeutic treatment of bladder cancer using, for example, a polynucleotide(s) encoding an interleukin(s), an interferon(s), a colony stimulating factor(s) and/or a tumor suppressor(s).
Inventor(s):	Esuvaranathan; Kesavan (Singapore, SG), Mahendran; Ratha (Singapore, SG), Lawrencia; Carmel (Singapore, SG)
Assignee:	Genecure Pte Ltd. (Singapore, SG)
Application Number:	11/986,829
Patent Claims:	1. A method of treating bladder cancer in a subject, the method comprising: delivering a transfection composition intravascularly into the bladder of a subject, such that bladder cancer cells of the subject are transfected with the polynucleotide, wherein the polynucleotide imparts anti-cancer activity against bladder cancer cells, wherein the transfection composition comprises: (i) a polynucleotide; (ii) a cationic lipid, a cationic polymer or a dendrimer, or combinations thereof; and (iii) a solubilized cholesterol preparation, wherein the solubilized cholesterol preparation comprises cholesterol solubilized with a cyclodextrin. 2. The method of claim 1, wherein the cyclodextrin is methyl-.beta.-cyclodextrin. 3. The method of claim 1, wherein the cyclodextrin is selected from the group consisting of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, sulfated beta-cyclodextrin, tertiary amine beta-cyclodextrin, quaternary amine beta-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2,6-di-O-methyl-beta-cyclodextrin, hydroxyethyl-beta-cyclodextrin, 6-deoxy-6-S-beta-D-galactopyranosyl-6-thio-cyclomalto-heptaose, sulfobutylether-beta-cyclodextrin, carboxymethyl-beta-cyclodextrin, carboxymethyl-ethyl-beta-cyclodextrin, diethyl-beta-cyclodextrin, dimethyl-beta-cyclodextrin, random methyl-beta-cyclodextrin, glucosyl-beta-cyclodextrin and maltosyl-beta-cyclodextrin. 4. The method of claim 1, wherein (ii) is a cationic lipid which is 1,2-diacyl-3-trimethylammonium propane (DOTAP). 5. The method of claim 1, wherein (ii) is a dendrimer which is a cationic dendrimer. 6. The method of claim 1, wherein the cationic lipid, cationic polymer or dendrimer is selected from the group consisting of dioleoyl phosphatidylethanolamine (DOPE), [2,3-bis(oleoyl)propyl]trimethyl ammonium chloride (DOTMA), dioctadecyl amido glycyl spermine (DOGS), dioctadecyl diammonium bromide (DODAB), dioctadecyl diammonium chloride (DODAC), 2,3dioleoyloxy-N-[sperminecarboxaminoethyl]-N--N-dimethyl-1-prop- anamimium (DOSPA), 3.beta.[N-n',N'-dimethylaminoethane)-carbamoyl]cholesterol, dioleoyl (DC-Chol), (1-[2-oleoyloxy-ethyl]-2-oleo yl-3-(2-hydroxyethyl) imidazolinium chloride (DOIC), dioleoyl phosphatidylcholine (DOPC), dimyristooxypropyl dimethyl hydroxyethyl ammonium bromide (DMRIE), polyaminodoamine (PAMAM), polylysine, polyhistidine, polyarginine, polyethyleneimine, poly(4-vinylpyridine), poly(vinylamine), poly(4-vinyl-N-alkyl pyridinium halide), or combinations thereof. 7. The method of claim 1, wherein the polynucleotide comprises at least one expression vector encoding at least one protein selected from the group consisting of interleukins, interferons, colony stimulating factors, anti-angiogenic factors, anti-metastatic factors, membrane receptors and tumor suppressors. 8. The method of claim 1, wherein the polynucleotide comprises an expression vector encoding a protein selected from the group consisting of interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-13 (IL-13), interleukin-18 (IL-18), interferon-.alpha., interferon-.beta., interferon-.gamma., granulocyte-macrophage colony stimulating factor (GMCSF), granulocyte colony stimulating factor (GCSF), p53, and an antagonist of vascular endothelial cell growth factor (VEGF). 9. The method of claim 1, wherein the polynucleotide comprises an expression vector encoding interleukin-2 (IL-2). 10. The method of claim 1, wherein the polynucleotide comprises an expression vector encoding granulocyte macrophage colony stimulating factor (GMCSF). 11. The method of claim 1, wherein the polynucleotide comprises an expression vector encoding interferon-.gamma.. 12. The method of claim 1, wherein the polynucleotide comprises at least one expression vector encoding two or more of interleukin-2 (IL-2), granulocyte macrophage colony stimulating factor (GMCSF) and interferon-.gamma.. 13. The method of claim 1, which further comprises performing an additional anti-bladder cancer treatment on the subject. 14. The method of claim 13, wherein the additional anti-bladder cancer treatment comprises Bacillus Calmette-Guerin (BCG) therapy.

Details for Patent 7,709,457

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Teknika Llc	TICE BCG	bcg live	For Injection	102821	06/21/1989		2019-09-01